Articles tagged with Cervical Cancer
The HALP score, a novel immune-nutritional marker, has been linked to prognostic ability in different cancer types. It integrates indicators of immune status and nutritional status, showing promise as a cost-effective biomarker.
Researchers found a connection between arthritis flare-ups and periodontitis, suggesting that regular dental check-ups could help prevent rheumatoid arthritis. The study also identified potential therapeutic targets for cancer, including the use of mouthwash to prevent flares.
A recent study by the University of Kentucky Markey Cancer Center validates a new radiopharmaceutical compound as a viable treatment option for patients with advanced cervical cancer. The radioactive drug, 212Pb-DOTAM-GRPR1, targets gastrin-releasing peptide receptor, a protein expressed by cancer cells.
Researchers identify the minimum contribution of TACC3 for FGFR3-TACC3 fusion protein activation, revealing a novel target for treating FGFR translocation-driven cancers. The study shows that clinically identified FGFR3-TACC3 fusion proteins differ in biological activity depending on specific breakpoints.
The ESMO Gynaecological Cancers Congress 2023 will present the latest treatments and insights for ovarian, uterine, cervical, and rare gynaecological cancers. Around 80 studies will be presented on strategies to overcome PARP inhibitors mechanisms of resistance in ovarian cancer.
The institutions will develop trials to screen cervical cancer patients in low-resource countries, aiming to prevent advanced cancer. The collaboration aims to achieve the World Health Organization's goal of eliminating cervical cancer by adapting and innovating prevention strategies.
A new study reveals that nearly one in five new cervical cancers diagnosed from 2009-2018 were in women 65 and older, with late-stage diagnoses increasing up to age 79. The study suggests that current screening guidelines may be failing these women, leading to lower survival rates.
The EMBRACE-I study demonstrated the superiority of personalized brachytherapy in treating locally advanced cervical cancer. A targeted approach using magnetic resonance imaging-defined tumor volume resulted in a high tumor control rate and low risk of recurrence.
Researchers at the University of Tokyo have developed artificial DNA that can target and kill cancer cells by binding to microRNA molecules. The DNA triggers an immune response that not only kills cancer cells but also prevents further growth of cancerous tissue.
A recent study found that many young cancer survivors decline HPV vaccination due to concerns about safety, importance, and timing. The research aims to address these concerns and provide health care providers with messaging tools to encourage survivors to receive the vaccine.
Despite decreases in some high-income countries, the global cervical cancer burden remains high due to inadequate screening and vaccination programs in low- and middle-income countries. The study highlights the need for scaling up HPV vaccination and screening efforts globally to achieve the WHO's 2030 elimination target.
Researchers found that lncRNA MVIH is overexpressed in cervical cancer tumors and associated with younger age, lymph node metastasis, tumor invasion depth, and squamous cell type. This suggests its potential as a diagnostic biomarker for cervical cancer.
A systematic review of national clinical practice guidelines in Europe found that fewer than half include HIV testing recommendations for patients with medical conditions indicating HIV infection. This omission hinders efforts to stop the spread of HIV through timely diagnosis, affecting the lives of people living with HIV.
A new study published in JAMA Internal Medicine suggests that more public health data is needed on the utilization of cervical cancer screening-associated services among older women. The analysis showed that over 1.3 million women received cervical cancer screening-associated services after age 65, with costs exceeding $83 million.
Researchers found a 3% per year increase in cervical cancer incidence in women in their early 30s, starting from 2012, and an increase in both localized and regional disease. The study suggests that improved screening rates are needed to address the rising incidence.
Population-based cancer screening rates declined during the pandemic, only to recover rapidly in initial stages; however, long-term follow-up reveals ongoing gaps in preventive care. The study suggests that prolonged disruptions in screening can have lasting effects on public health.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
Researchers have identified two distinct molecular subgroups of cervical cancer, C1 and C2, which differ in their clinical aggressiveness and response to treatment. The study suggests that determining the subgroup of a patient's cervical cancer could provide additional prognostic information for planning treatment.
A new study found that sexual side effects of cancer treatment are discussed less frequently with female patients, who are asked about their sexual health 1 in 10 times, compared to 9 in 10 men. The disparity is also observed in clinical trials nationwide.
USC Norris Comprehensive Cancer Center is partnering with the Chinatown Service Center to address disparities in cervical cancer screening and treatment. The partnership aims to optimize access, shorten diagnosis-to-treatment timeframes, and enhance quality of care for Chinese and Latina women in Los Angeles.
A UTHealth Houston study found regional disparities in cancer screening rates tied to social vulnerability, with lower rates in more vulnerable counties. The study analyzed 3,141 US counties and discovered significant differences in breast, cervical, and colorectal cancer screenings.
A study of 3,141 US counties found that counties with higher social vulnerability had lower rates of recommended breast, cervical, and colorectal cancer screenings. The findings suggest that addressing social determinants of health may be crucial for improving cancer screening rates.
Advanced cervical cancer rates have been rising in the US, with a significant increase among White women and higher prevalence among Black women, particularly those in their mid-to-late 50s. The study found that obesity and older age at first birth may contribute to the rise in this type of cervical cancer.
Researchers have found that treating high-grade squamous intraepithelial lesions (HSILs) in people with HIV significantly decreases the progression to anal cancer. The ANCHOR trial enrolled over 4,000 participants and showed a 57% reduction in anal cancer cases.
A systematic review and meta-analysis of 39 publications found a global association between COVID-19 measures and reduced breast, colorectal, and cervical cancer screenings. This could lead to an increase in avoidable cancer deaths.
A recent survey revealed significant gaps in cancer screening among women aged 50-64, with rates as low as 50% for colorectal cancer and 46.5% for both cancers. The study found that patient-centered approaches to screening can facilitate timely testing and management of abnormal results.
Scientists have created new fluorescent chemical compounds for photodynamic therapy of cancerous tumors, which can stain affected tissues and destroy tumor cells without harm to healthy ones. The compound containing pyrene shows the highest fluorescent and anticancer activity.
A national survey study found that colorectal cancer screening increased via stool testing while colonoscopy decreased during the pandemic. Breast and cervical cancer screenings also saw modest declines.
A study of 1.3 million women in England found that screening every five years is as effective as three-year intervals for those with a negative HPV screen, and may even prevent more cancers. The study provides reassurance to women aged 24-49 who test negative for HPV.
A recent study reveals that sexual minority individuals are less likely to undergo cervical cancer screening, with Hispanic individuals facing the most significant disparities. The analysis of 2015–2018 data from the National Health Interview Survey found that white sexual minority participants and Hispanic sexual minority participants...
Researchers have developed mini organs that replicate the cervical tissue, allowing for the study of normal physiology, disease development, and infectious processes. The creation of these mini organs, known as organoids, offers new opportunities for personalized medicine, finding new active substances, and modeling diseases.
Cancer incidence is projected to double in SSA by 2040, with 1.4 million cases per year expected without rapid interventions. Women are more affected by cancer than men in the region, with breast and cervical cancers among the most common types.
Canada's cancer rates are declining overall, but new cases and deaths are on the rise due to an aging population and growing numbers. Despite this, efforts in cancer prevention, screening, early detection, and treatment have led to improved survival rates for those diagnosed with cancer.
A new study published in the Journal of Medical Screening found that over half of eligible women (51.4%) prefer self-sampling for cervical cancer screening, as it addresses concerns about embarrassment and provides more flexibility. The study also suggests that many regular screeners may switch to self-sampling if offered the option.
The program aims to increase trained cancer researchers in Tanzania and prepare them for HIV-associated cancer diagnostics, genomics, and therapy. It will focus on molecular detection, epidemiology, and biology of common HIV-associated malignancies.
A recent study by Cathy Bradley found that Medicaid patients with continuous coverage have better cancer survival rates compared to those without. Conversely, screening programs for low-income women may not be as effective as general insurance coverage.
A randomized controlled trial of 2,275 women in Kenya found a single dose of the human papillomavirus (HPV) vaccine to be highly effective. The study results support the adoption of a single-dose HPV vaccination, which could increase accessibility in low- and middle-income countries.
Researchers found that changes in viral communities may enable persistent HPV infection and progression to cancer, associated with bacterial composition and inflammation. Low Lactobacillus abundance and bacteriophage presence were also linked to increased risk.
A new study reveals that the COVID-19 pandemic has led to significant declines in cancer screening rates across the US, particularly for colorectal, cervical, breast, and lung cancers. The American Cancer Society's National Consortium has announced nine recommendations to increase cancer screening rates and improve quality care.
Researchers found that adding atezolizumab to chemoradiation treatment was safe and demonstrated immune activation in women with node-positive, locally advanced cervical cancer. The study also showed increased peripheral blood T-cell receptor clonal expansion and tumor-associated T-cell clones.
A new phenomenon was discovered where increased pressure leads to a sudden burst of rapid and coordinated cellular motion, spraying outwards from the tumour. This fluid-like pushing mechanism can kill cancer cells but also enables them to survive and multiply in new environments.
A new study found significant increases in HPV-associated anal, oropharyngeal, and vulvar cancer in the US, particularly in low-income counties with high smoking rates. The increases were slower in higher-income areas.
The Cancer Prevention & Research Institute of Texas has awarded a grant extension to Dr. Rakhshanda Rahman, allowing her to provide no-cost mammograms and Pap smears to underinsured and uninsured women in the Permian Basin. The program aims to address high cervical cancer incidence and mortality rates in West Texas.
A new study found that cervical cancer incidence is increasing in low-income US counties, while plateauing in high-income counties. The study analyzed data from 2000 to 2018 and estimated trends by county-level household income and smoking prevalence.
Researchers have found that HPV and Chlamydia pathogens work together to reprogram cells, leading to cancer. The study used 3D organoids to investigate the interactions between the pathogens and tissues affected by disease.
New studies from Michigan Medicine researchers aim to remove financial barriers for patients who receive abnormal test results, enabling them to complete the diagnostic process. The findings suggest that removing cost barriers could save lives by increasing screening uptake, particularly among women and underserved populations.
Results from the Phase III EMPOWER trial demonstrate the efficacy of PD-1 inhibitor cemiplimab in improving overall survival for women with recurrent and/or metastatic cervical cancer. The study showed a 31% lower risk of death in patients receiving cemiplimab compared to chemotherapy.
A study found that risks of preterm birth, infant sepsis, and other adverse outcomes associated with CIN-3 treatment have decreased over time. Pregnancies after CIN-3 treatment should be managed as 'high risk' to reduce these risks.
Women treated for cervical neoplasia grade 3 show declining risks of preterm birth, neonatal sepsis, and infant death after treatment. The study suggests that these high-risk pregnancies should be managed with careful consideration.
Ovarian cancer death rates are predicted to decrease by 17% in the UK and 7% in EU countries in 2022. The main contributor is the long-term use of oral contraceptives, reducing the risk by 40%. Other factors include improved diagnosis, treatment, and advancements in treatments for other cancers.
Rates of cervical cancer screening have dropped in the US, with significant disparities found across sociodemographic groups. The study highlights the need for targeted campaigns to address lack of knowledge as the primary reason for not receiving timely screenings.
A nationwide study found decreased cervical cancer incidence and death rates among women and girls aged 15-24 after HPV vaccine introduction. The decline was more pronounced in the younger age group compared to those aged 25-29 and 30-39, suggesting a potential association with vaccination.
The study found that cervical cancer rates in NYC neighborhoods with low socioeconomic status are significantly higher than those with high socioeconomic status, highlighting the need for neighborhood-level interventions to increase access to preventive services.
A population-based study found a significant association between neighborhood socioeconomic inequality and cervical cancer rates in NYC. The study revealed that low-socioeconomic status neighborhoods had higher cervical cancer incidence rates compared to higher-socioeconomic status neighborhoods.
Research conducted by Brigham and Women's Hospital found that cervical cancer rates are significantly higher in low SES neighborhoods of New York City. The study analyzed data from two databases and calculated a 73 percent greater risk of cervical cancer in these neighborhoods compared to high-SES areas.
A randomized controlled trial in Kenya showed a single dose of the human papillomavirus (HPV) vaccine was highly effective at 18 months, with efficacy comparable to multiple doses. The findings could hasten vaccinations and bring renewed energy to global efforts to eliminate cervical cancer.
A new study published in The Lancet confirms that HPV vaccination has led to a significant reduction in cervical cancer rates in England. Women who were vaccinated between the ages of 12-13 had an 87% lower incidence of cervical cancer compared to previous generations.
A new study improves AI diagnoses by penalizing algorithms for false negatives, which can be more urgent than accuracy. Researchers achieved significant improvements in precision and recall for chronic kidney disease and other conditions using cost sensitivity techniques.
A study by University of New Mexico researchers found that 65% of women with a normal prior co-test had undergone re-screening within three years, far more often than recommended. Meanwhile, some women were not re-tested for over five years after a negative co-test or cytology alone, increasing their risk for poor outcomes.
A recent study found that HPV vaccine hesitancy has either stabilized or increased in some ethnic and age groups, highlighting the need for targeted campaigns to encourage hesitant families. The study also identified several reasons why parents hesitate to vaccinate their children with the HPV vaccine.